Rheumatology Network Editorial Staff

The U.S. Food and Drug Administration has granted pre-market approval to Mainstay Medical Holdings for the production of an implantable neurostimulator for chronic low back pain.

All good relationships are built on solid foundations, including the doctor-patient relationship. In this interview with Dr. Candace Feldman, M.D., MPH, ScD, of Brigham and Women’s Hospital in Boston, we explore factors that may impinge good outcomes for lupus patients.

In a guidance recently issued for pediatric rheumatic disease patients, the American College of Rheumatology stresses the importance of continuing vaccinations, but forgoing antibody testing for COVID-19--at least for now.

Researchers writing in the current issue of Arthritis and Rheumatology report that a blood thinner may have potential as a preventive treatment for osteoarthritis.

In this week's news roundup from Rheumatology Network, we feature a series of studies that focus on new treatments for rheumatic disease. We also highlight the newly approved secukinumab (Cosentyx, Novartis) for active non-radiographic axial spondyloarthritis (axSpA). Today, we feature a discussion with Dr. Alexis Ogdie-Beatty and Kelly Gavigan, the lead researcher on a recent study about the overlap between axSpA and fibromyalgia.

Secukinumab, an IL-17a inhibitor currently approved in the United States for moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis, has been approved by the U.S. Food and Drug Administration for the treatment of active non-radiographic axial spondyloarthritis.

Axial psoriatic arthritis is sometimes confused with ankylosing spondylitis. What are the features that distinguish these conditions from each other? In this quiz, test your knowledge about this and other features of PsA.